BACKGROUND: The results of a recent study demonstrated an association between myoid differentiation and an adverse prognosis in adult patients with pleomorphic sarcoma, as determined by 5-year metastasis-free survival rates. METHODS: To confirm the importance of muscle differentiation on prognosis in a well controlled clinical context, 92 samples from patients with pleomorphic sarcoma of the extremity from a single institution were immunostained with 4 monoclonal antibodies believed to be correlated with myoid differentiation: alpha-smooth muscle actin, muscle-specific actin, desmin, and myoglobin. RESULTS: Forty-two cases were positive for at least 1 muscle marker and 50 cases were uniformly negative. Between the two groups, there was no significant difference in tumor size, tumor extent, or patient age found; however, histologic grade was significantly higher (P = 0.038) in the myoid tumors. The 5-year survival differed significantly between patients with myoid tumors (35%) and those without myoid tumors (65%) (P = 0.0054). Myoid differentiation remained an adverse prognostic indicator after adjusting for clinically significant factors (i.e., histologic grade, tumor size, tumor extent, and patient age) (P = 0.01) (hazard ratio, 2.39; 95% confidence interval, 1.24-4.63). Furthermore, there was an inverse relation found between the number of myoid markers present and survival (P = 0.004). CONCLUSIONS: Myoid differentiation was found to be an independent indicator of adverse prognosis in adult patients with pleomorphic spindle cell sarcoma of the extremity. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11617
BACKGROUND: The results of a recent study demonstrated an association between myoid differentiation and an adverse prognosis in adult patients with pleomorphic sarcoma, as determined by 5-year metastasis-free survival rates. METHODS: To confirm the importance of muscle differentiation on prognosis in a well controlled clinical context, 92 samples from patients with pleomorphic sarcoma of the extremity from a single institution were immunostained with 4 monoclonal antibodies believed to be correlated with myoid differentiation: alpha-smooth muscle actin, muscle-specific actin, desmin, and myoglobin. RESULTS: Forty-two cases were positive for at least 1 muscle marker and 50 cases were uniformly negative. Between the two groups, there was no significant difference in tumor size, tumor extent, or patient age found; however, histologic grade was significantly higher (P = 0.038) in the myoid tumors. The 5-year survival differed significantly between patients with myoid tumors (35%) and those without myoid tumors (65%) (P = 0.0054). Myoid differentiation remained an adverse prognostic indicator after adjusting for clinically significant factors (i.e., histologic grade, tumor size, tumor extent, and patient age) (P = 0.01) (hazard ratio, 2.39; 95% confidence interval, 1.24-4.63). Furthermore, there was an inverse relation found between the number of myoid markers present and survival (P = 0.004). CONCLUSIONS: Myoid differentiation was found to be an independent indicator of adverse prognosis in adult patients with pleomorphic spindle cell sarcoma of the extremity. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11617
Authors: Pawel Kurzawa; John T Mullen; Yen-Lin Chen; Sarah E Johnstone; Vikram Deshpande; Ivan Chebib; G P Nielsen Journal: Am J Surg Pathol Date: 2020-06 Impact factor: 6.394
Authors: Anne M Mills; Andrew H Beck; Kelli D Montgomery; Shirley X Zhu; Inigo Espinosa; Cheng-Han Lee; Subbaya Subramanian; Christopher D Fletcher; Matt van de Rijn; Robert B West Journal: Am J Surg Pathol Date: 2011-04 Impact factor: 6.394
Authors: Elizabeth G Demicco; Genevieve M Boland; Kari J Brewer Savannah; Kristelle Lusby; Eric D Young; Davis Ingram; Kelsey L Watson; Marshall Bailey; Xiangqian Guo; Jason L Hornick; Matt van de Rijn; Wei-Lien Wang; Keila E Torres; Dina Lev; Alexander J Lazar Journal: Histopathology Date: 2015-01-12 Impact factor: 5.087